Kalpataru Multiplier Ltd.

Our Bank & DP Click for Online Payment MF portfolio login smart way to invest in gold
Sovereign gold bond(SGB) Exchange trades funds(ETF)
CLOSE

Download our app Kalpataru Share trading from Google/App Store and transfer fund instantly.

Company Profile
more from company profile
HomeMarkets Company Profile Smart Quotes

Smart Quotes

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE944.4551.25 (+5.74 %)
PREV CLOSE () 893.20
OPEN PRICE () 887.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1034361
TODAY'S LOW / HIGH ()886.50 949.00
52 WK LOW / HIGH ()660.05 1059.6
NSE944.8551.85 (+5.81 %)
PREV CLOSE() 893.00
OPEN PRICE () 886.90
BID PRICE (QTY) 944.85 (1)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10308556
TODAY'S LOW / HIGH() 885.55 950.00
52 WK LOW / HIGH ()726.8 1059
BSE NSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 1981

Management Info :

V C Nannapaneni - Chairman V C Nannapaneni - Managing Director

Registered Office :

Address : Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040-23547532

Registrar's Details : Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE, NSE
NEWS
16Feb Natco Pharma jumps on getting CDSCO’s
Natco Pharma is currently trading at Rs. 885.35, up by 63.25 points or 7..
14Feb Natco Pharma gets CDSCO’s approval for
Natco Pharma has received approval from Central Drugs Standard Control O..
13Feb Natco Pharma gets EIR for API division
Natco Pharma has received Establishment Inspection Report (EIR) from U.S..
13Feb NATCO Pharma informs about press rele
NATCO Pharma has informed that it enclosed the Press Release regarding t..
12Feb Natco Pharma reports 14% rise in Q3 co
Natco Pharma has reported results for third quarter ended December 31, 2..
Financials
in Millions
QTR Dec 25 ANNUAL 25
Net Profit106918504
Gross Profit 1252 22260
Operating Profit 175624656
Net Sales 528840945
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Procter&Gamble Healt (BSE)
 5160.70 (1.79%)
M.Cap ( in Cr)
8566.44
Torrent Pharma (BSE)
 4398.70 (2.02%)
M.Cap ( in Cr)
148872.00
Ipca Laboratories (BSE)
 1523.35 (3.14%)
M.Cap ( in Cr)
38648.03
Eris Lifesciences (BSE)
 1384.60 (2.46%)
M.Cap ( in Cr)
19179.93
Glenmark Pharma (BSE)
 2061.95 (1.18%)
M.Cap ( in Cr)
58188.40
Shareholding Pattern
PROMOTERS 49.48%
NON-INSTITUTION 29.97%
FI/BANKS/INSURANCE 3.5%
MUTUAL FUNDS/UTI 1.6%
GOVERNMENT 0%
FII 0%
Mf Holding
ATTENTION INVESTORS

Kalpataru Multiplier Ltd.

Kalpataru is a wishful Divine Tree and in present context a widely Trusted, Time tested and Transparent Share Broker, Mutual Fund Distributor and D.P. of this region.

Mobile Trading App
Mobile Trading IOS App
Call Us 0755-4350141/142/143, 9425008895
Mutual Funds 0755-4276725, 4276726
Email Uskmlho@kalpatarumulti.com

registration nos:

Kalpataru Multiplier Ltd.: SEBI Regn. No. INZ000259437

Registered address: Kalpataru House, 18 Itwara, Bhopal (MP) – 462001

Member Member ID
Bombay Stock Exchange Ltd.(BSE) 3016
National Stock Exchange Ltd. 11152
Multi Commodity Exchange(MCX) 16020

Depository Participant of CDSL DP-ID 12031600

(SEBI Regn No. IN-DP-CDSL-221-2003)

In absence of response/ complaint not addressed to your satisfaction, you may lodge a complaint and reach out to us on:

SMART ODR PORTAL @ https://smartodr.in/login

Copyright © 2016 Kalparatu Multiplier Ltd.
Designed ,Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
SENSEX82225.92-1068.74 (-1.28%)
NIFTY25424.65-288.35 (-1.12%)
Dow Jones 49174.50370.44 (0.76%)
Nasdaq 22863.68236.41 (1.04%)
CLOSE Disclosure
CLOSE

INFORMATION UNDER THE HEAD SHOULD BE ADDED AS FOLLOWS

  • Sharing of trading credentials - login id & password including OTP's.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing / selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through Whatsapp, Telegram, YouTube, Facebook, SMS, Calls, etc.
  • Trading in "Options" based on recommendations from unauthorised / unregistered investment advisors and influencers.
CLOSE SEBI